Lal, Anoushka P., Foong, Yi Chao, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas‑Robledo, Simón, Moghadasi, Abdorreza Naser, Sanfilippo, Paul G., Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan, Alroughani, Raed, Spelman, Tim, Kermode, Allan G., Surcinelli, Andrea, Laureys, Guy, Eichau, Sara, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Maimone, Davide, Rath, Louise, McCombe, Pamela, Spitaleri, Daniele, Sanchez-Menoyo, Jose Luis, Yetkin, Mehmet Fatih, Baghbanian, Seyed Mohammad, Karabudak, Rana, Al-Asmi, Abdullah, Jakob, Gregor Brecl, Khoury, Samia J., Etemadifar, Masoud, Levitz, David, van Pesch, Vincent, Buzzard, Katherine, Taylor, Bruce, Butzkueven, Helmut, Van der Walt, Anneke, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas. Springer; 2024. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.

Yeh, Wei Z., Van Der Walt, Anneke, Ozakbas, Serkan, Buzzard, Katherine, Habek, Mario, John, Nevin A., Prat, Alexandre, Girard, Marc, Duquette, Pierre, Baghbanian, Seyed Mohammad, Hodgkinson, Suzanne, Van Pesch, Vincent, Skibina, Olga G., Laureys, Guy, Willekens, B, Prevost, J, Foschi, M, De Gans, K, Horakova, D, Havrdova, EK, Karabudak, R, Patti, F, Mccombe, PA, Kalincik, Tomas, Maimone, D, Altintas, A, Ampapa, R, Spitaleri, D, Gerlach, OHH, Sa, MJ, Hughes, S, Gouider, R, Mrabet, S, Macdonell, RA, Alroughani, Raed, Turkoglu, R, Cartechini, E, Al-Asmi, A, Soysal, A, Oh, J, Muros-Le Rouzic, E, Guye, S, Pasquarelli, N, Butzkueven, H, Jokubaitis, VG, Kermode, Allan G., MSBase Study Group,, Fabis-Pedrini, Marzena J., Carroll, William M., Lechner-Scott, Jeannette, Boz, Cavit. Wolters Kluwer Health; 2024. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.